REGULATORY

• Chuikyo Reps Warn Each Other over 2% Adjustment Rate in Drug Price Revisions
  April 22, 2021

• MSD Developing 2-Dose Regimen for 9-Valent HPV Vaccine: Panel
  April 22, 2021

• Olumiant Now in Line for Japan Nod for COVID-19 Pneumonia
  April 22, 2021

• Vaccine Industry Group Calls for Govt’s Control Functions for Infectious Diseases
  April 21, 2021

• Japan Officially Announces CEA-Based Prices for Kymriah/Trelegy, Effective July 1
  April 21, 2021

• FPMAJ Chief Calls for Uninterrupted Govt Support for Japan-Made Vaccines Even in Ordinary Times
  April 20, 2021

• Over 50% of Itraconazole ADR Reporting Comes from Pharmacists in October-December: PMDA
  April 20, 2021

• Automatic Listing for Approved Drugs Erodes Financial Predictability: MOF
  April 19, 2021

• MHLW to Revoke Approval of 12 Kobayashi Kako Products as Documents Fabricated
  April 19, 2021

• Industry Veteran Prods Appropriate Evaluation for Innovation: LDP Confab
  April 16, 2021

• Chuikyo Receives Report on Fertility Treatment Survey, Awaits Guidelines to Discuss Coverage
  April 16, 2021

• 2 New Payer Members Make Chuikyo Debut
  April 15, 2021

• Ultomiris Now Braced for Price Cut as Chuikyo OKs CEA Results
  April 15, 2021

• LDP Project Team to Compile Proposal on Japan-Made Vaccine Development
  April 15, 2021

• Bayer’s Heart Failure Med Vericiguat Up for 2nd PAFSC Review
  April 15, 2021

• MHLW Presents Discussion Timeline for FY2022 Reform
  April 15, 2021

• Olumiant Up for PAFSC Review for COVID-19 on April 21, Combo Use with Veklury
  April 15, 2021

• Drug Pricing Rules to Be Applied to Breyanzi: Chuikyo
  April 15, 2021

• Yescarta to Join NHI Price List on April 21, Gets CEA-Tweak from Get-Go
  April 14, 2021

• Kymriah to Get 4.3% Reduction, Trelegy 0.5% Cut in 1st CEA-Based Price Tweak
  April 14, 2021

ページ

• « 先頭
• ‹ Prev
• …
• 149
• 150
• 151
• 152
• 153
• 154
• 155
• 156
• 157
• …
• Next ›
• 最終 »